← Stocks · GOSS record
Signal record & history · Trifecta Signals
Gossamer has been flagged by the Trifecta screener 6 times since 2022. 4 signals confirmed; the median confirmed signal is down 94.7% since its Early Signal.
Price refreshes every trading day after the close.
Full interactive chart ↗ · partner link
Daily closes · through the most recent close
Price history from Jan 2018 · Signal tracking began Jan 2022
Headline statistics: confirmed signals only, measured from the confirmation price.
First signal Jan 2022 · Latest Feb 2026 · Confirmed 4 of 6 Early · Latest close in the chart data: Thu, Nov 5, 2026
Groups are mutually exclusive — every confirmed signal sits in exactly one.
Since January 2022, Gossamer has had six Early signals, four confirmed. Three of the four decided signals gained +10% within 90 days, and zero of four finished ahead of the S&P 500 since confirmation. Three signals carried a caution flag. Two Early signals never confirmed and count in no statistic.
Every Early signal in the record, newest first.
Members see every signal below, and the group mix above.
Membership unlocks the complete signal timeline for GOSS and every other stock in the record — group tags, caution flags, and the full screener.
Already a member? Sign in and this page unlocks.
Gossamer Bio sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. At a market value of about $61 million, it sits in the small-cap group.
The strongest run on Gossamer Bio’s record followed a confirmation in May 2022, gaining about 63% over the following 90 days. A March 2023 signal in the Downtrend group gained about 13% over the next 90 days. Classification adds texture: revenue was shrinking by about 58% at the time, and it sat in the mid-cap group when that signal fired.
GOSS closed Thursday, November 5 at $9.42, down 5.3% on the day. The last five sessions span about $9.28 to about $10.38.
